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Background and Purpose—Although a genetic contribution to ischemic stroke is well recognized, only a handful of stroke 
loci have been identified by large-scale genetic association studies to date. Hypothesizing that genetic effects might be 
stronger for early- versus late-onset stroke, we conducted a 2-stage meta-analysis of genome-wide association studies, 
focusing on stroke cases with an age of onset <60 years.
Methods—The discovery stage of our genome-wide association studies included 4505 cases and 21 968 controls of European, 
South-Asian, and African ancestry, drawn from 6 studies. In Stage 2, we selected the lead genetic variants at loci with 
association P<5×10−6 and performed in silico association analyses in an independent sample of ≤1003 cases and 7745 
controls.
Results—One stroke susceptibility locus at 10q25 reached genome-wide significance in the combined analysis of all 
samples from the discovery and follow-up stages (rs11196288; odds ratio =1.41; P=9.5×10−9). The associated locus is 
in an intergenic region between TCF7L2 and HABP2. In a further analysis in an independent sample, we found that 2 
single nucleotide polymorphisms in high linkage disequilibrium with rs11196288 were significantly associated with total 
plasma factor VII–activating protease levels, a product of HABP2.
Conclusions—HABP2, which encodes an extracellular serine protease involved in coagulation, fibrinolysis, and 
inflammatory pathways, may be a genetic susceptibility locus for early-onset stroke.   (Stroke. 2016;47:00-00. 
DOI: 10.1161/STROKEAHA.115.011328.)
Key Words: factor VII ◼ genetics ◼ genome-wide analysis ◼ ischemic stroke ◼ stroke
Stroke is the fourth leading cause of death in the United States and a major cause of long-term disability among 
adults.1 Ischemic stroke, the predominant type of stroke, has 
a multifactorial pathogenesis, with heritability estimated at 
37%–38%.2,3 One approach to gain insights into the molecu-
lar basis underlying stroke susceptibility is to identify stroke 
susceptibility genes and then assess the functions of these 
genes. A handful of stroke susceptibility loci have recently 
been identified.4,5 Additional stroke susceptibility loci can per-
haps be identified by studying special high risk populations or 
focusing on specific subtypes of stroke.
We focus in this study on identifying susceptibility loci 
associated with early-onset stroke, based on the premise that 
variants associated with younger onset stroke might have 
higher penetrance and effect sizes than those associated with 
older onset stroke. Disease-associated variants have been 
associated with early-onset forms of numerous other com-
plex diseases, including breast cancer, diabetes mellitus, and 
heart disease. Although a minority of stroke cases occur at 
young age, the best available evidence suggests that stroke at 
younger ages has a stronger genetic basis than stroke occur-
ring at older ages.4
To identify loci associated with early-onset stroke, we con-
ducted a 2-stage genome-wide association study (GWAS), in 
which we meta-analyzed 6 individual studies in the Discovery 
Stage and then followed up suggestively associated loci in 
independent samples. In a combined analysis of the discov-
ery and follow-up stages, we detected significant evidence 
for association to a locus on chromosome 10q25 that met 
genome-wide significance thresholds. Further analyses of this 
locus suggest a possible link to hyaluronan-binding protein 2 
(HABP2), which encodes Factor VII–activating protease.
Methods
Genome-Wide Association Meta-Analysis
The discovery stage for the GWAS meta-analysis included 4505 early-
onset ischemic stroke cases and 21 968 controls from 6 case–control 
studies (Table). Our analysis included only early-onset ischemic 
stroke cases, defined as stroke age of onset <60 years using study-
specific diagnostic criteria. Two of the discovery stage studies by de-
sign included only young onset cases (Genetics of Early-Onset Stroke 
[GEOS] and Stroke in Young Fabry Patients [SIFAP]). Four of the 
discovery studies included individuals of European ancestry only, one 
included individuals of South-Asian ancestry only, and one included 
individuals of both European ancestry and African Americans. Three 
of the studies by design included previously genotyped controls se-
lected from the same geographic region as the cases and genotyped 
on the same single nucleotide polymorphism (SNP) array.
The follow-up stage included a total of 1003 independent, ear-
ly-onset cases and 7745 controls from 3 independent case–control 
studies of European ancestry populations. Study-specific subject 
inclusion/exclusion criteria are provided in the online-only Data 
Supplement, and study characteristics and sample sizes are summa-
rized in Table; Tables I and II in the online-only Data Supplement.
All studies were genotyped on Illumina SNP arrays (San Diego, 
CA). Following data cleaning, principal component analyses were 
performed to identify population outliers and to determine popu-
lation substructure for adjustment in the association analyses. 
Quality control filters for samples and SNPs were applied within 
each study before imputation (Tables III and IV in the online-on-
ly Data Supplement). Imputation was performed in the discovery 
stage samples based on either the 1000 Genomes Phase 1 interim 
reference panel or the Phase 1 integrated reference panel using 
IMPUTE2 software (Table III in the online-only Data Supplement).6 
Postimputation filters further excluded SNPs from association anal-
yses having minor allele frequency (MAF) <1% or imputation qual-
ity score (INFO) <0.3. In the follow-up stage studies, all studies 
were imputed using 1000 Genomes Phase 1 integrated reference 
panel before association testing.
For the 3 studies that by design included previously geno-
typed controls (Risk Assessment of Cerebrovascular Events Study 
[RACE] I, SIFAP, and Wellcome Trust Case–Control Consortium 2 
[WTCCC2]-UK), additional quality control steps, such as removing 
SNPs with evidence for differential missingness, were performed to 
ensure comparability of genotyping performance between cases and 
controls. Q-Q plots for all studies revealed no evidence for genomic 
inflation (lambdas ranging from 1.00 to 1.06) and the meta-analysis 
was further genomic control-corrected.
Detailed information about the genotyping platforms, genotype 
cleaning procedures, imputation process, and association analysis 
modeling is described in the online-only Data Supplement and Tables 
III and IV in the online-only Data Supplement.
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GWAS analysis was performed within each study using a logis-
tic regression model with case/control status as the dependent vari-
able and SNP allelic dosage as the independent variable to test for 
a multiplicative effect of the SNP on risk of ischemic stroke. The 
study-specific effect of each SNP, expressed as the ln-transformed 
odds ratio (OR) or β, was obtained after adjusting for the effect of 
population structure and/or additional study-specific variables before 
meta-analysis.
To account for the multiethnic composition of studies, we per-
formed a transethnic GWAS meta-analysis that combined association 
summary statistics from European, South-Asian, and African ethnic 
groups (n=4505 cases and 21 968 controls from all studies). The fol-
low-up stage (3 studies, n=1003 cases and 7745 controls) consisted 
of European Caucasians only. Ethnic-specific β estimates (obtained 
by meta-analyzing studies of the same ethnicity) were meta-analyzed 
assuming a random effect model to allow for heterogeneity be-
tween different ethnic groups. Post analysis, we excluded SNPs with 
MAF<1% and INFO<0.3. We additionally excluded SNPs with high 
between-study heterogeneity (I2>50%) and SNPs present in only 1 
ethnic group.
All meta-analyses were performed using the GWAMA soft-
ware and repeated using the fixed-effect model as well as Han and 
Eskin’s random effects model (implemented with METASOFT 
software) to evaluate the consistency of associations. Meta-
analyses were performed by 2 independent analysts, and the re-
sults were consistent.
SNPs with P<5×10−6 in the discovery stage and having high 
linkage disequilibrium (LD) partners that also showed evidence for 
association were assessed for association in the follow-up stage via 
in silico look-ups. A joint analysis of the combined discovery and 
follow-up studies was performed by meta-analyzing the study-specif-
ic estimates from all studies to obtain joint ORs and P values under 
fixed effect model. We considered a P value <5×10−8 from the joint 
analysis as our threshold for genome-wide statistical significance.
We also performed an European-only GWAS meta-analysis 
(discovery stage: n=2567 cases and 17 163 controls from 5 stud-
ies) in which study-specific β estimates were meta-analyzed us-
ing the inverse variance–weighted approach assuming a fixed-effect 
model. SNPs absent in >2 European studies (European-only meta-
analysis) were excluded from the analysis.
We estimated that the combined sample provided 80% power 
to detect an odds ratio of 1.36 in the transethnic meta-analysis at 
5% MAF assuming a significance level (α) of 5×10−8. The minimal 
detectable odds ratio at 80% power in the European-only meta-anal-
ysis was 1.48. Power calculations were obtained using the QUANTO 
software.
Extension to Older Onset Stroke
We tested whether SNPs associated with young onset stroke 
were also associated with stroke in older populations through 
in silico look-ups in the METASTROKE consortium,7 a consor-
tium comprising 15 studies of predominantly older stroke cases. 
METASTROKE studies already included in either the discovery 
or follow-up stage of the early-onset stroke GWAS were excluded 
from this analysis. Study-specific GWAS results obtained from 
METASTROKE were provided to Y.-C. Cheng for meta-analy-
sis. Basic study design features and cohort characteristics of the 
METASTROKE studies have been published previously7 and are 
summarized in the online-only Data Supplement and Table V in the 
online-only Data Supplement.
Table.  Characteristics of Participating Studies
Study
Cases Controls
Ancestry CountrySubjects, n Age, mean (SD) Male, n (%) Subjects, n Age, mean (SD) Male, n (%) External Control
Stage 1: discovery stage
  CADISP 555 43.7 (9.9) 339 (61.1) 9259 N/A N/A No EA Belgium, 
France, 
Germany, Italy, 
Switzerland, and 
Finland
  GEOS EA 448 41.0 (7.0) 275 (61.4) 498 39.5 (6.7) 282 (56.6) No EA USA
  GEOS AA 381 41.9 (6.8) 207 (54.3) 352 40.0 (6.8) 196 (55.7) No AA USA
  MILANO 201 45.0 (10.4) 120 (60.9) 407 50.8 (8.1) 357 (87.8) No EA Italy
  RACE 1 1218 50.1 (9.9) 638 (52.4) 1158 51.9 (7.9) 613 (53) PROMIS South Asian Pakistan
  RACE 2 339 50.2 (9.2) 272 (80.4) 3295 60.9 (13.2) 1838 (55.8) PROMIS South Asian Pakistan
  SIFAP 981 41.7 (7.4) 599 (61.1) 1824 55.2 (11.6) 899 (49.3) KORA EA Germany
  WTCCC2-UK 382 51.9 (7.3) 228 (59.7) 5175 52 2611 (50.5) British Birth Cohort 
and UK Blood 
Service Control
EA UK
  Total 4505 21968
Stage 2: Follow-up stage
  ASGC 227 52.3 (8.7) 151 (66.5) 1244 66.3 (7.5) 625 (50.2) No EA Australia
  WTCCC2-
Munich
275 48.8 (8.5) 188 (68.4) 797 62.7(10.9) 410 (51.4) KORA EA Germany
  Immunochip 501 48.7–53.4. 58%–73% 5704 N/A 27%–50% No EA Belgium, 
Germany, 
Poland, Sweden, 
and UK
  Total 1003 7745
AA indicates African ancestry; ASGC, Australian Stroke Genetics Collaborative; CADISP, Cervical Artery Dissection and Ischemic Stroke Patients; EA, European 
ancestry; GEOS, Genetics of Early-Onset Stroke; KORA, Cooperative Health Research in the Region of Augsburg [Germany]) study; MILANO, Besta Stroke Study; RACE, 
Risk Assessment of Cerebrovascular Events Study; SIFAP, Stroke in Young Fabry Patients; and WTCCC2, Wellcome Trust Case–Control Consortium 2.
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Association of SNPs at 10q25 With Factor 
VII–Activating Protease Protein Levels
A single locus on chromosome 10q25 near HABP2, the gene en-
coding factor VII–activating protease (FSAP), met genome-wide 
statistical significance in the joint meta-analysis. Because we con-
sidered HABP2 to be a strong biological candidate gene for ischemic 
stroke, we tested for association of the index SNPs at the associated 
locus with variation in plasma FSAP levels, which were measured 
in relatively healthy participants of the Sahlgrenska Academy Study 
on Ischemic Stroke (SAHLSIS8; see online-only Data Supplement). 
FSAP levels, measured by an FSAP-specific ELISA as previously de-
scribed,9 were logarithmically transformed before analysis. Analyses 
were conducted in normolipidemic control subjects only (n=125) be-
cause FSAP antigen and activity levels are increased in both ischemic 
stroke and hyperlipidemia.9
The statistical significance level was set at 0.05, and P values were 
2-tailed. Statistical tests were performed using the SPSS Statistics 
software program.
Results
Genome-Wide SNP Association With Early-Onset 
Ischemic Stroke
The transethnic meta-analysis included 13 439 215 SNPs 
having MAF>1% in at least 2 ethnic groups. Approximately 
57%, 35%, and 8% of the cases were from European, South-
Asian, and African ancestry, respectively (Table; Table I in 
the online-only Data Supplement). The mean age of stroke 
cases ranged between 41 and 52 years. There was evidence 
for genomic deflation (λ=0.90; Figure IB in the online-only 
Data Supplement) under the random effect model, but no evi-
dence of genomic inflation or deflation under the fixed effect 
model (λ=1.007). The strongest association was with a cluster 
of 12 SNPs (P values<5×10−6) spanning a 22 kb region (chr10: 
115042323-115064197bp; Figure 1B; Table VI in the online-
only Data Supplement). The associated cluster fell within an 
intergenic region between TCF7L2 and HABP2 on chromo-
some 10q25.3 as shown in Figure 2 (lead SNP rs11196288; 
OR=1.39, P=1.24×10−7, effect allele=G, random effect 
model). Results of the leading SNP associations for the trans-
ethnic analysis remained similar when analyzed using the Han 
and Eskin’s Random Effects model (rs11196288; OR=1.40, 
P=1.25×10−7) and fixed effect model (rs11196288; OR=1.39, 
P=1.24×10−7).
The 10q25.3 locus was the only locus with P<5×10−6 and 
was taken forward for follow-up analysis. The index SNP 
(rs11196288) was not genotyped in the WTCCC Immunochip 
study. In meta-analysis of the 2 remaining follow-up studies 
(n=502 cases and 2041 controls), this SNP showed significant 
evidence for significance (OR=1.83, P value =0.03). In the 
combined analysis of both discovery and follow-up studies, 
the 10q25.3 locus was genome-wide significant with minimal 
heterogeneity between studies (rs11196288: between-study 
heterogeneity I2=1.6%, P=0.42; OR=1.41, P=9.5×10−9 under 
the fixed effect model and P=1.5×10−8 under the random effect 
model; Table VII in the online-only Data Supplement). The 
direction of effect for the lead SNP, rs11196288, was consis-
tent in 9 out of the 10 studies (Figure 3). Notably, the study 
with the inconsistent direction of effect (Besta Stroke Study 
[MILANO]; OR=0.93, 95% confidence interval [CI]=0.39–
2.21; P=0.86) also had the lowest imputation quality score 
for this SNP (INFO=0.67), whereas the other 9 studies had 
excellent imputation quality (INFO ranging between 0.96 and 
0.99).
The European ancestry genome wide association analy-
sis included 2567 cases and 17 163 controls from 5 stud-
ies in the discovery stage (Cervical Artery Dissection and 
Ischemic Stroke Patients [CADISP], GEOS European ances-
try, MILANO, SIFAP, and WTCCC2-UK) and was based on a 
total of 10 537 953 SNPs with MAF>1% in the study popula-
tion. Following meta-analysis and after excluding a single iso-
lated SNP showing marginal evidence for association, a total 
of 21 SNPs from 4 loci showed suggestive associations with P 
Figure 1. Genome-wide association results of early-onset ischemic stroke based on transethnic meta-analysis (A) and European-only 
meta-analysis (B). Red line: P=5×10−8; grey line: P=5×10−6.
 at UniversitÃƒÂ  degli Studi di Brescia on January 21, 2016http://stroke.ahajournals.org/Downloaded from 
Cheng et al  GWAS of Young-Onset Ischemic Stroke  5
values <5×10−6 (Figure 1A; Figure IA in the online-only Data 
Supplement). However, none reached genome-wide signifi-
cance (P value <5×10−8). There was no evidence for genomic 
inflation (λ=1.004). The 4 suggestively associated loci, each 
represented by the 2 most significant SNPs, are listed in Table 
VII in the online-only Data Supplement. Of note, one of these 
loci includes Factor V (F5), a well-known stroke candidate 
gene.10,11 Of the 4 loci identified in the European-only meta-
analysis, none showed strong evidence for association in the 
follow-up stage (all stage 2 P values >0.22; Table VII in the 
online-only Data Supplement).
Secondary analyses of the associations between 
rs11196288 and ischemic stroke subtypes based on the 8 stud-
ies in the discovery phase revealed nominally significant asso-
ciations with all 3 major stroke subtypes under the random 
effect model: cardioembolic stroke (OR=1.34; P=0.02), large 
artery atherosclerotic stroke (OR=1.65; P=0.01), and small 
vessel stroke (OR=1.57; P=0.003). For large artery atheroscle-
rotic stroke, there was substantial heterogeneity in effect size 
between studies (I2=40%). In addition, rs11196288 showed a 
strong association with undetermined stroke, which accounted 
for 41% of all early-onset stroke cases in the discovery phase 
studies (OR=1.44, P=3×10−5). Evidence for association with 
stroke of other determined pathogenesis could not be evaluated 
because of limited number of cases. A further genome-wide 
meta-analysis of stroke subtypes was performed as an explor-
atory analysis as it was extremely underpowered; this provided 
no evidence for subtype-specific associations (Table VIII and 
Figures II and III in the online-only Data Supplement.)
We used the Ensemble Variant Effect Predictor tool to pre-
dict function of the index SNPs and SNPs in high LD with 
them. From these analyses, we identified 2 SNPs predicted 
Figure 2. Regional plot of the chr10q25.3 locus from transethnic 
association analysis in the discovery stage. Recombination rate 
was based on 1000 Genomes EUR data. Plot was generated 
using LocusZoom software.
Figure 3. Forest plot of rs11196288 at 
10q25.3, including discovery and follow-
up studies, in transethnic analysis. AA 
indicates African ancestry; ASGC, Aus-
tralian Stroke Genetics Collaborative; 
CADISP, Cervical Artery Dissection and 
Ischemic Stroke Patients; CI, confidence 
interval; EA, European ancestry; GEOS, 
Genetics of Early-Onset Stroke; MILANO, 
Besta Stroke Study; RACE, Risk Assess-
ment of Cerebrovascular Events Study; 
SIFAP, Stroke in Young Fabry Patients; 
and WTCCC2, Wellcome Trust Case–
Control Consortium 2.
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to be regulatory region variants that were in high LD with the 
index SNP at 10q25. Rs1338423 (r2=0.88 with rs11196288) 
and rs4918806 (r2=1 with rs11196288) both fall in an open 
chromatin region. Rs4918806 additionally falls in a promoter 
flanking region and a CCCTC-binding factor binding site.
Associations of Previously Known Stroke-Relevant 
Loci and the Risk of Early-Onset Ischemic Stroke
Using the discovery stage samples, we examined associations 
between early-onset ischemic stroke and 8 loci previously 
associated with ischemic stroke in GWAS of predominantly 
European older stroke cases.3,7,12–18 We observed nominally 
significant associations (ie, P<0.05) with early-onset ischemic 
stroke at 4 loci (ALDH2, PITX2, CDKN2B-AS1, and ABO) in 
the European-only analyses (Table IX in the online-only Data 
Supplement). Interestingly, ABO was also associated with 
undetermined stroke, a predominant stroke subtype in early-
onset stroke patients. In transethnic meta-analysis, SNPs at 
PITX2 and ABO, but not CDKN2B-AS1 or ALDH2, showed 
nominal association with stroke (Table IX in the online-only 
Data Supplement).
Effect of the 10q25 Locus on Risk of Ischemic 
Stroke in Older Populations From the 
METASTROKE Consortium
We further examined whether the 2 lead SNPs identified in 
our early-onset stroke GWAS were associated with the risk 
of ischemic strokes at older age of onset by performing an in 
silico look-up of association results from the METASTROKE 
consortium. Of the 15 discovery studies in METASTROKE, 
13 had genotyped rs11196288 and rs4918806, a perfect proxy 
(r2=1) for rs61872854. Five of these studies were already 
included in either the discovery or follow-up stage of the 
early-onset stroke GWAS, leaving 8 studies for the in silico 
look-up. Mean age of stroke in these studies ranged from 57.3 
to 81.6 years. Study level results were used because individ-
ual-level data are not available through METASTROKE. No 
significant associations were observed for either rs11196288 
(OR=1.08, 95% CI=0.96–1.22; P=0.18) or rs4918806 
(OR=1.04, 95% CI=0.94–1.14; P=0.47) in the meta-anal-
ysis of the 8 studies. However, when ranking these studies 
by the mean age of stroke cases (Figure 4), the study with 
youngest mean age (ie, Atherosclerotic Risk in Community 
[ARIC], mean age onset =57.3 years) showed the stron-
gest risk associated with the 2 SNPs (OR=1.51), while the 
study with oldest mean age (ie, Cardiovascular Health Study 
[CHS], mean age onset =81.6 years) showed a nonsignificant 
inverse association with the 2 early-onset stroke–associated 
SNPs (OR=0.67). Results remained similar when the 1 study 
with >30% of early-onset stroke cases (Heart Protection 
Study [HPS]) was removed from the analyses (rs11196288: 
OR=1.09, 95% CI=0.96–1.23, P=0.18; rs495366: OR=1.03, 
95% CI=0.93–1.14, P=0.55).
Associations With Plasma FSAP Levels
Of the 12 SNPs at 10q25 showing suggestive associations with 
early-onset ischemic stroke, 2 (rs7906302 and rs1338423) had 
previously been genotyped in SAHLSIS and were tested for 
association with circulating FSAP levels (n=125 normolipid-
emic control subjects). The risk alleles associated with stroke 
susceptibility were significantly associated with higher FSAP 
levels at both loci (rs7906302: 15.1 versus 11.7 μg/mL for 
(AC+CC) versus AA genotypes; P=0.026 and rs1338423: 15.6 
versus 11.7 μg/mL for AG versus AA genotype; P=0.012; see 
Figure 5). The risk allele frequencies for rs7906302 (allele C) 
and rs1338423 (allele G) are 0.04 and 0.03 in SAHLSIS con-
trols, respectively. Both SNPs are in high LD (r2=0.88; Table 
VI in the online-only Data Supplement) with the index SNP 
rs11196288.
Discussion
Although a genetic predisposition to stroke is widely acknowl-
edged, our understanding of genetic basis for ischemic stroke 
is limited. We have focused in this study on early-onset isch-
emic stroke, a form of stroke for which there may be a genetic 
enrichment. Our study included a total of 4505 early-onset 
stroke cases and 21 968 controls from 3 ethnic groups, thus 
making it the largest GWAS of early-onset stroke carried out 
to date by far.
Our analysis identified a novel locus at 10q25 strongly 
associated with early-onset ischemic stroke with an estimated 
≈1.40-fold increased risk associated with the risk variant. The 
10q25 association showed consistent direction of effect in 9 
out of the 10 studies, but achieved genome-wide significance 
only in the combined analyses of discovery and follow-up 
samples. Further replication of this locus in independent sam-
ples is warranted. Despite this limitation, this locus is of great 
interest because of its proximity to HABP2. HABP2 encodes 
FSAP, an extracellular serine proteinase that cleaves urinary 
plasminogen activator, coagulation factor VII, and tissue fac-
tor pathway inhibitor and helps regulate coagulation, tissue 
remodeling, and inflammation.19–22 Previous studies reported 
elevated levels of FSAP activity in patients with coronary 
artery disease23 and ischemic stroke.9 Rare genetic variants 
(eg, the Marburg I polymorphism) in HABP2 have also been 
associated with increased risk of deep venous thrombosis,24 
carotid stenosis,25 and stroke.26 Recent animal studies have 
also suggested that FSAP activity may modulate stroke-asso-
ciated brain injury.27
Although the locus associated with early-onset ischemic 
stroke in our study is located in an intergenic region ≈253 kb 
away from HABP2, several of the associated SNPs are pre-
dicted to have regulatory properties and associate with circulat-
ing levels of FSAP, implicating a possible mechanism leading 
to increased risk of early-onset stroke via HABP2. Interestingly, 
the previously known Marburg I polymorphism in HABP2 
(rs7080536) showed no association with early-onset stroke in 
our analysis (data not shown). Further studies are needed to 
identify the causal variant(s) tagged by these associated SNPs 
as well as their functional properties, leading to the increased 
risk of early-onset stroke. In contrast to most of the previously 
known stroke-relevant loci, our data are consistent with this 
10q25 locus being associated with multiple stroke subtypes, a 
finding consistent with the possible thrombotic mechanism of 
HABP2 that can lead to increased coagulation and, therefore, 
susceptibility across the different stroke subtypes.
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Our study also suggests that the effects of the 10q25 locus 
may be specific to (or at least more pronounced in) early-
onset stroke because the association was largely absent in 
METASTROKE studies, which consisted of predominantly 
older stroke cases. Unfortunately, we did not have access 
to large case–control cohorts consisting of stroke cases >60 
years only, and therefore, we were unable to compare the 
allele frequency of rs11196288 between younger and older 
stroke cases directly to assess its effect on age of stroke onset. 
However, even within METASTROKE, there is a hint of an 
age dependency, with the locus effect appearing strongest 
in the study with the youngest mean age of onset (ie, ARIC, 
mean age=57.3 years, OR=1.51) and weakest in the study 
with the oldest mean age of stroke onset (ie, CHS, mean 
age=81.6 years, OR=0.67). An age-dependency for genetic 
effects would be parallel to prior reports that other risk factors 
may have large effects in younger versus older-onset stroke.28 
Further studies on possible interactions between genetic vari-
ants and environmental exposures are needed to elucidate how 
the genetic risk to stroke changes over the life span and in the 
presence of environmental challenges.
Despite the lack of association between 10q25 and 
risk of stroke at older age of onset, some of the previously 
reported stroke loci (identified via studying mainly older 
stroke cases3,7,13–18) showed nominal associations with early-
onset stroke in our study, including PITX2 with cardioembolic 
stroke, CDKN2B-AS1 with large artery stroke, ALDH2 with 
Figure 4. Associations of rs11196288 and rs4918896 at 10q25.3 with risk of stroke in METASTROKE studies, by mean age of stroke 
cases. ARIC indicates Atherosclerotic Risk in Community; BRAINS, Bio-Repository of DNA in Stroke; CHS, Cardiovascular Health Study; 
CI, confidence interval; HPS, Heart Protection Study; HVH, Heart and Vascular Health Study; ISGS/SWISS, Ischemic Stroke Genetics 
Study/Siblings With Ischemic Stroke Study.
Figure 5. Plasma factor VII activating protease (FSAP) levels are 
associated with rs7906302 and rs1338423 in normolipidemic 
controls in Sahlgrenska Academy Study on Ischemic Stroke 
(SAHLSIS). Median and interquartile range (IQR) of FSAP accord-
ing to genotype in controls. Differences in logFSAPag levels were 
calculated with Student’s t test. *P<0.05.
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overall ischemic stroke, and ABO with cardioembolic, large 
artery stroke and overall ischemic stroke. Our findings are 
thus consistent with early-onset and late-onset stroke sharing 
some of the same genetic susceptibility loci.
Our study was powered to detect an odds ratio of 1.36 
for an SNP with MAF=0.05, which was slightly smaller than 
the effect size (OR=1.41) actually observed for the associ-
ated SNP. However, even including 4500 early-onset stroke 
cases, we were unable to identify any subtype-specific stroke 
susceptibility loci in this early-onset stroke population using 
genome-wide association approach, possibly because of the 
small number of cases within each stroke subtype. Obtaining 
sufficient early-onset cases within each stroke subtype 
remains a significant challenge in future studies, and col-
laborative efforts will be needed to overcome this limitation. 
In the European GWAS analysis, we failed to replicate F5, 
a key protein in the coagulation pathway, as an early-onset 
stroke susceptibility locus. Previous evidence from candidate 
gene studies has long suggested that genetic variants of F5 
predispose to stroke, the most conspicuous example being 
the Factor V Leiden (FVL) variant.10,11,29 However, a recent 
large-scale meta-analysis suggested that the reported associa-
tion between FVL and early-onset ischemic stroke was more 
pronounced among studies where cases were selected on the 
basis of having cryptogenic stroke or recruited from a sub-
set of patients referred for a thrombophilic work-up, and the 
FVL-stroke association is much smaller among studies with 
unselected cases.10 This may explain the lack of consistent 
results observed in our GWAS because cases included in our 
analyses were unselected, and thus, the genetic effect may be 
less prominent. Given the complexity of the study populations 
included in this study, significant phenotypic heterogeneity 
likely remains among stroke cases even within this early-onset 
stroke group.
In summary, we have identified a novel locus at 10q25 
associated with all ischemic strokes in young adult popula-
tion. This locus is located near HABP2, which encodes an 
extracellular serine protease involved in coagulation, fibrino-
lysis, and even inflammatory pathways, suggesting a plausible 
biological mechanism leading to increased risk of stroke. This 
locus did not appear to have a significant effect in older cases, 
indicating this may be a genetic susceptibility locus for early-
onset stroke. Further replication of the 10q25 locus and addi-
tional studies investigating the potential age of onset effect 
are needed.
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Details of the Discovery and Follow-up Stages for GWAS 
 
Discovery GWAS Stage (Stage 1). The Discovery stage for the GWAS meta-analysis included a 
total of 4,505 early-onset cases and 21,968 controls from 6 studies: Cervical Artery Dissections and 
Ischemic Stroke Patients study (CADISP), Genetics of Early-onset Stroke study (GEOS), Milano study 
(MILANO), Stroke in Young Fabry Patients (SIFAP), Risk Assessment of Cerebrovascular Events 
Study (RACE) and UK samples from Wellcome Trust Case Control Consortium 2 (WTCCC2-UK).  
Four of these studies (CADISP, MILANO, SIFAP, WTCCC2-UK) included individuals of European 
ancestry only, while RACE included individuals of South-Asian ancestry from Pakistan and GEOS, 
which recruited participants from the Greater-Baltimore Washington Area, USA, included individuals of 
both European ancestry and African Americans.  All studies used a case-control study design. External 
controls (genotyped separately from the cases) were used for three studies: SIFAP (controls from 
Cooperative Health Research in the Augsburg Region ["Kooperative Gesundheitsforschung in der 
Region Augsburg"], KORA), RACE (controls from the Pakistan Risk of Myocardial Infarction Study 
[PROMIS]), and WTCCC2-UK (controls from the 1958 British Birth cohort and the UK Blood Service 
control group).   RACE cases were genotyped in two phases (RACE1 and RACE2) and thus were 
analyzed separately and then meta-analyzed together to provide RACE study-specific estimates. Study-
specific subject inclusion/exclusion criteria are provided in the Supplementary Data, and summary of 
study characteristics, including their sample size, are listed in Table 1 and Supplemental Table I.  
Follow-up Stage (Stage 2).  The Follow-up stage included a total of 1,003 independent, early-
onset cases and 7,745 controls from the Australia Stroke Genetics Collaborative (ASGC), Munich 
samples from WTCCC2 (Munich) and the WTCCC Immunochip Study (Immunochip). All three studies 
were of European ancestry and used the case-control study design, and subjects included in the Follow-
up stage were independent of those included in the Discovery. The ASGC and Munich studies were 
genotyped using whole-genome array while WTCCC Immunochip Study were genotyped using Illumina 
ImmunoChip.  
 
Ischemic stroke was defined according to predefined study-specific criteria, generally as a focal 
neurological deficit lasting greater than 24 hours or, if lasting less than 24 hours, with neuroimaging 
evidence. The majority of cases were first-ever strokes. Stroke subtypes were defined according to the 
Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria.1 
 
 
Study-specific GWAS of the Discovery Cohorts 
 
 The 6 Discovery cohorts included 3 studies with internal controls (GEOS, CADISP, and 
MILANO) and 3 studies with external controls (SIFAP, RACE, and WTCCC2-UK), the latter including 
external controls by design in order to maximize the number of cases that could be genotyped.  All 
studies were genotyped using whole-genome SNP arrays from Illumina (San Diego, CA, USA).  
Extensive quality control was carried out at each site at both the sample and SNP level.  Study samples 
were removed from analyses if they had low genotyping call rates, exhibited mismatches between 
genetic and reported genders or relatedness, or were outliers from the population on the basis of 
principal component analysis of SNPs. SNPs were excluded prior to imputation if they had high missing 
call rates (missing rate >5%), were monomorphic, or deviated from Hardy-Weinberg equilibrium (HWE 
p<0.0001 for most studies).  Detailed information about the genotyping platforms, genotype cleaning 
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procedures, imputation process, and association analysis modeling is described in Supplemental Tables 
III (Discovery phase) and IV (Follow-up phase).  
 
Additional SNP level QC was performed for the studies with external controls to ensure that 
artifactual differences in allele frequencies between cases and controls did not arise due to differences in 
genotyping performance between genotyping centers.  Within each study, cases and controls were 
merged for a second round of SNP cleaning to remove SNPs with differential missingness between 
cases and controls and to check for cyptic relatedness.  In the GEOS, SIFAPS, and RACE I studies, 
genotyping concordance rates between cases and controls were evaluated by re-genotyping ~30 control 
samples that had been previously genotyped along with the cases, after which SNPs with ≥ 1 discordant 
genotype in a sample were removed from analysis.  Principal components were calculated within the 
merged cases and control groups and outlier samples were removed from analysis.  After QC, a genome-
wide association study (GWAS) was performed within each study to check genomic inflation and ensure 
that QC had successfully removed false associations potentially resulting from the study design. Lambda 
values across the studies revealed no evidence for genomic inflation (lambdas: 0.98, 0.98, 1.05, 1.01, 
and 1.02 for GEOS-EUR, GEOS-AFR, SIFAP, RACE I, and WTCCC2-UK, respectively). 
 
 
Testing for association of index SNPs with FSAP levels in the SAHLSIS 
SAHLSIS participants had previously been genotyped on the Illumina Human OmniExpress 750K array 
at the Broad Institute at Harvard Medical School (Boston, USA). This array included two SNPs 
(rs7906302 and rs1338423) that were in high linkage disequilibrium (LD) with the young onset stroke-
associated SNP (r2=0.88; D’=1 for both SNPs with the index SNP).  These two SNPs were in high LD 
with each other (r2 = 0.77).  Because the number of subjects with two copies of the minor allele of 
rs7906302 was small (2 individuals), the minor allele was treated as absent (AA) versus present (AC + 
CC). For rs1338423, no individuals had two copies of the minor allele (G) and comparisons were 
therefore made between the AA and AG genotypes. 
 
 
Description of Stage 1 and Stage 2 Studies 
 
Australian Stroke Genetics Collaborative (ASGC) 
ASGC stroke cases comprised stroke patients of European ancestry who were admitted to four clinical 
centers across Australia (The Neurosciences Department at Gosford Hospital, Gosford; the Neurology 
Department at John Hunter Hospital, Newcastle; The Queen Elizabeth Hospital, Adelaide; and the Royal 
Perth Hospital, Perth) between 2003 and 2008. Stroke was defined by World Health Organization 
criteria as a sudden focal neurological deficit of vascular origin, lasting more than 24 h and confirmed 
by imaging, such as computerized tomography (CT) and/or magnetic resonance imaging (MRI) brain 
scan. Other investigative tests such as electrocardiogram, carotid Doppler and trans-esophageal 
echocardiogram were conducted to define ischemic stroke mechanism as clinically appropriate. Cases 
were excluded from participation if they were aged <18 years, were diagnosed with hemorrhagic stroke 
or had transient ischemic attack rather than ischemic stroke or if they were unable to undergo baseline 
brain imaging. On the basis of these criteria, a total of 1,230 ischemic stroke cases were included in the 
current study. Ischemic stroke subtypes were assigned using TOAST criteria on the basis of clinical, 
imaging and risk factor data. 
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ASGC controls were participants in the Hunter Community Study (HCS), a population-based cohort of 
individuals aged 55–85 years, predominantly of European ancestry and residing in the Hunter Region in 
New South Wales, Australia. Participants were randomly selected from the New South Wales State 
electoral roll and were contacted by mail between 2004 and 2007. Consenting participants completed 
five detailed self-report questionnaires and attended the HCS data collection center, at which time a 
series of clinical measures were obtained. A total of 1,280 HCS participants were genotyped for the 
current study. 
 
All study participants gave informed consent for participation in genetic studies. Approval for the 
individual studies was obtained from the relevant institutional ethics committees. 
 
Cervical Artery Dissection and Ischemic Stroke Patients (CADISP) 
The CADISP Study aims primarily at identifying genetic and environmental risk factors for cervical 
artery dissection (CeAD), a major cause of ischemic stroke in young adults. We included 942 CeAD 
patients in the CADISP study in 2004-2009 (CADISP-1; 170 Finns and 772 non-Finnish Europeans). 
Additional 451 CeAD patients of European origin were recruited in 2008-2010, exclusively for the 
CADISP-genetics project, in some CADISP centers and additional European and US centers (CADISP-
2). To assess the specificity of risk factors for CeAD, we also recruited 583 patients with an IS 
attributable to other causes (non-CeAD IS, 162 Finns and 421 non-Finnish Europeans from Belgium, 
France, Germany, Italy, and Switzerland), frequency-matched on age, sex and geographical origin with 
CADISP-1 CeAD patients. Of these, a total of 555 non-CeAD IS patients aged < 60 years, who were 
successfully genotyped and met genotyping quality control criteria, were available for the present 
analysis. The abstracted hospital records of cases were reviewed and adjudicated for IS subtype by a 
neurologist in each participating center. Each item required for the subtype classification was also 
recorded in a standardized fashion. Based on this, IS subtypes were then centrally readjudicated by a 
panel of neurologists, in agreement with the TOAST system1, using the more detailed subtype 
description from Ay et al.2 DNA samples were genotyped on an Illumina Human610-Quad or 
Human660W-Quad BeadChip® at the Centre National de Génotypage [CNG], Evry, France. The 
majority of controls (N=9,046, of which 74 Finns and 8,972 non-Finnish Europeans) were selected from 
an anonymized control genotype database at the CNG, in order to match cases for ethnic background, 
based on principal component analysis. European reference samples from the genotype repository at the 
CNG were also analyzed simultaneously to provide improved geographical resolution. Additional 
Finnish controls were recruited within the CADISP study, both from the general population and among 
spouses and unrelated friends of CADISP patients, within the Helsinki area. A total of 234 individuals 
were eligible for genotyping at the CNG. Of these, 213 individuals who were genotyped successfully 
and met quality control criteria were available for the present analysis. Individuals were excluded if they 
were unexpected duplicates, gender discrepancy and unexpected relatedness. After quality control, we 
performed genotype imputation to the nonmonomorphic SNPs described in the 1000 genomes phase I v3 
reference panel. 
 
Genetics of Early-onset Stroke Study (GEOS) 
GEOS is a population-based case-control study designed to identify genes associated with early-onset 
ischemic stroke and to characterize interactions of identified stroke genes and/or SNPs with 
environmental risk factors.3; 4  Participants were recruited from the greater Baltimore-Washington area 
in 4 different time periods:  Stroke Prevention in Young Women-1 (SPYW-1) conducted from 1992-
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1996, Stroke Prevention in Young Women-2 (SPYW-2) conducted from 2001-2003, Stroke Prevention 
in Young Men (SPYM) conducted from 2003-2007, and Stroke Prevention in Young Adults (SPYA) 
conducted in 2008.  Case participants were hospitalized with a first cerebral infarction identified by 
discharge surveillance from one of the 59 hospitals in the greater Baltimore-Washington area and direct 
referral from regional neurologists. The abstracted hospital records of cases were reviewed and 
adjudicated for ischemic stroke subtype by a pair of neurologists according to previously published 
procedures with disagreements resolved by a third neurologist. The ischemic stroke subtype 
classification system retains information on all probable and possible causes, and is reducible to the 
more widely used TOAST system that assigns each case to a single category.   Control participants 
without a history of stroke were identified by random-digit dialing and were balanced to cases by age 
and region of residence in each recruitment periods.  Genomic DNA was isolated from a variety of 
sample types, including cell line, whole blood, mouth wash and buccal swab.  Samples were genotyped 
at the Johns Hopkins Center for Inherited Disease Research (CIDR) using the Illumina HumanOmni1-
Quad_v1-0_B BeadChip (Illumina, San Diego, CA, USA). Individuals were excluded if they were 
unexpected duplicates, gender discrepancy and unexpected relatedness. For this analysis, 5.1% of cases 
and 0.6% of controls that had a history of MI (based on self-report) were removed from analysis. 
 
Milano 
This study includes consecutive Italian patients referred to Besta Institute from 2000 to 2009 with stroke 
and included in the Besta Cerebrovascular Diseases Registry (CEDIR). Ischemic stroke cases, first ever 
or recurrent, confirmed on brain imaging, were selected for this study. All cases were of self-reported 
Caucasian ancestry and had clinically relevant diagnostic workup performed. All cases were phenotyped 
by an experienced stroke neurologist according to TOAST criteria, based on relevant clinical imaging 
and available information on cardiovascular risk factors. Controls are Italian individuals enrolled within 
the PROCARDIS Study, with no personal or sibling history of coronary heart disease before age 66 
years. 
 
Stroke in Young Fabry Patients (SIFAP) 
SIFAP study is a multicenter study carried out to determine the frequency of Fabry disease in an 
unselected group of young patients (18 – 55 years of age) with acute cerebrovascular events (CVE) 
defined as having had an acute ischemic stroke or transient ischemic attack less than 3 months before 
enrollment into the study.  For this project, about ischemic stroke cases recruited from 15 sites 
throughout Germany and determined not to have Fabry Disease were included in the analysis.  All were 
of European ancestry and had age of first stroke of 18-55 years.  The diagnosis of Fabry disease was 
based in males as well as in females in the first level on the sequencing data of the entire exon structure 
including promoter of the α-galactosidase gene. In cases where a mutation was detected biochemical 
analysis was done. Stroke cases from SIFAP were genotyped at CIDR using the Illumina Human Omni 
2.5M-Quad array and controls free of cardiovascular diseases were selected from the KORA Study 
previously genotyped at CIDR in the same platform.  The Cooperative Health Research in the Region of 
Augsburg (KORA) study is a population-based study of cardiovascular and metabolic traits carried out 
in the region of Augsburg, Southern Germany.  Extensive care will be taken in the data cleaning process 
to minimize artifactual differences in allele frequencies between cases and controls that may have 
occurred due to cases and controls being genotyped at different times (although on the same platform 
and in the same laboratory).   
 
Risk Assessment of Cerebrovascular Events (RACE) Study, Pakistan 
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RACE is a retrospective case-control study designed to identify and evaluate genetic, lifestyle and 
biomarker determinants of stroke and its subtype in Pakistan. Samples were recruited from six hospital 
centers in Pakistan. Cases were eligible for inclusion in the study if they: (1) are aged at least 18 years; 
(2) presented with a sudden onset of neurological deficit affecting a vascular territory with sustained 
deficit at 24 hours verified by medical attention within 72 hours after onset (onset is defined by when the 
patient was last seen normal and not when found with deficit); (3) the diagnosis was supported by 
CT/MRI; and (4) presented with a Modified Rankin Score of < 2 prior to the stroke. TOAST and 
Oxfordshire classification systems were used to sub-phenotype all stroke cases. Control participants 
were individuals enrolled in the Pakistan Risk of Myocardial Infarction Study (PROMIS), a case-control 
study of acute MI based in Pakistan. Controls in PROMIS were recruited following procedures and 
inclusion criteria as adopted for RACE cases. In order to minimize any potential selection biases, 
PROMIS controls selected for this stroke study were frequency matched to RACE cases based on age 
and gender and were recruited in the following order of priority: (1) non-blood related or blood related 
visitors of patients of the out-patient department; (2) non-blood related visitors of stroke patients; (3) 
patients of the out-patient department presenting with minor complaints. 
 
Wellcome Trust Case-Control Consortium 2 (WTCCC2) 
The WTCCC2 samples were genotyped as part of the WTCCC 2 ischemic stroke study. Stroke cases 
included samples recruited by investigators at St. George's University London (SGUL) and University 
of Oxford in the UK and the Department of Neurology, Klinikum Großhadern, Ludwig-Maximilians-
University, Munich.  
 
The SGUL collection comprised 1224 ischemic stroke samples from a hospital based setting. All cases 
were of self-reported Caucasian ancestry. Ischemic stroke subtypes were determined according to 
TOAST criteria based on relevant clinical imaging and available information on cardiovascular risk 
factors. The University of Oxford collection comprised 896 ischemic stroke cases, consecutively 
collected as part of the Oxford vascular study (OXVASC). Cases were of self-reported Caucasian 
ancestry, and ischemic stroke subtypes were determined according to TOAST criteria based on relevant 
clinical imaging. The University of Edinburgh collection comprised 727 ischemic stroke cases, 
consecutively collected as part of the Edinburgh Stroke Study. Cases were of self-reported Caucasian 
ancestry, with ischemic stroke subtypes determined according to TOAST criteria based on relevant 
clinical and imaging data.  
 
The Munich samples included 1383 ischemic stroke cases. Cases were consecutive European 
Caucasians recruited from a single dedicated Stroke Unit at the Department of Neurology, Klinikum 
Großhadern, Ludwig-Maximilians-University, Munich. Ischemic stroke subtypes were determined 
according to TOAST criteria based on relevant clinical and imaging data. Controls for the UK samples 
were drawn from shared WTCCC controls obtained from the 1958 Birth Cohort. This is a prospectively 
collected cohort of individuals born in 1958 (http://www.b58cgene.sgul.ac.uk/), and ascertained as part 
of the national child development study (http://www.cls.ioe.ac.uk/studies.asp?section=000100020003). 
Data from this cohort are available as a common control set for a number of genetic and epidemiological 
studies. For the German samples controls were Caucasians of German origin participating into the 
population KORAgen study (www.gsf.de/kora/en/english.html). This survey represents a gender- and 
age stratified random sample of all German residents of the Augsburg area and consists of individuals 25 
to 74 years of age, with about 300 subjects for each 10-year increment. All controls were free of a 
history of stroke or transient ischemic attack. 
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WTCCC Immunochip 
The Immunopchip samples consisted of 5 cohorts of patients of European ancestry with ischemic stroke. 
Participating centers were based in Belgium, Germany, Poland, Sweden, and the UK (2 cohorts, one 
from London [Imperial College; the BRAINS study] and one from Glasgow). All cohorts provided 
geographically and ancestry-matched controls. For the purposes of meta-analysis, the UK cohorts were 
treated as a single center in line with previous analyses undertaken in WTCCC2. The 5 discovery phase 
cohorts used the commercially available Immunochip array (Illumina, San Diego, CA), comprising 
~200,000 SNPs. Genotyping for the 5 case cohorts was performed at the Sanger Centre, Hinxton, 
Cambridge, UK. Swedish controls were provided and genotyped by the Swedish SLE network, Uppsala, 
Sweden. Belgian control samples were provided through the efforts of the International Multiple 
Sclerosis Genetics Consortium. The Immunochip datasets were each imputed separately to the 1,000 
Genomes Phase 1 integrated variant set (March 2012) using IMPUTE v2.2.2. 
 
Studies in METASTROKE consortium (excluding studies included in either Stage 1 or Stage 2)  
 
The Atherosclerosis Risk in Communities Study (ARIC) 
The ARIC study is a prospective population-based study of atherosclerosis and clinical atherosclerotic 
diseases in 15,792 men and women, including 11,478 non-Hispanic white participants, drawn from 4 
U.S. communities (Suburban Minneapolis, Minnesota; Washington County, Maryland; Forsyth County, 
North Carolina, and Jackson, Mississippi). In the first three communities, the sample reflects the 
demographic composition of the community. In Jackson, only black residents were enrolled. Ancestry 
was self-reported during an interview. Over 99% self-identified as either white or black. Only self-
identified whites were included in the analyses.5 Hospitalized strokes that occurred by December 31, 
2007 (median follow-up, 18.7 years) were included in the analyses. During annual telephone contacts, 
trained interviewers asked each ARIC participant to list all hospitalizations during the past year. 
Hospital records for any hospitalizations identified were then obtained. Moreover, all local hospitals 
annually provided lists of stroke discharges (International Classification of Diseases, Ninth Revision, 
Clinical Modification codes 430 to 438), which were surveyed for ARIC participant discharges. Details 
on quality assurance for ascertainment and classification of stroke are described elsewhere.6 Briefly, the 
stroke diagnosis was assigned according to criteria adapted from the National Survey of Stroke.7 Strokes 
secondary to trauma, neoplasm, hematologic abnormality, infection, or vasculitis were excluded, and a 
focal deficit lasting <24 hours was not considered to be a stroke. Out-of-hospital stroke was not 
ascertained and validated; thus, these potential stroke events are not included. Strokes were classified 
into hemorrhagic stroke (subarachnoid and intracerebral hemorrhage) and ischemic stroke (thrombotic 
and embolic brain infarction). A stroke was classified as ischemic when a brain CT or MRI revealed 
acute infarction and showed no evidence of hemorrhage. All definite ischemic strokes were further 
classified as lacunar, nonlacunar thrombotic, or cardioembolic on the basis of the recorded 
neuroimaging results. A stroke was classified as “lacunar” when 2 criteria were met: (1) typical location 
of the infarct (basal ganglia, brain stem, thalamus, internal capsule, or cerebral white matter); and (2) 
infarct size of ≤2 cm or unstated size.8 Definite or probable “cardioembolic” stroke required either (1) 
autopsy evidence of an infarcted area in the brain and a source of possible cerebral emboli in a vessel or 
the presence of an aembolus in the brain or (2) medical record evidence of a possible noncarotid source 
of embolus such as moderate or greater valvular heart disease, atrial fibrillation, cardiac or arterial 
procedure (e.g., cardiac catheterization, open heart surgery, cerebral angiography, and carotid 
endarterectomy), or intracardiac thrombus. Definite or probable ischemic strokes that were not classified 
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as lacunar or cardioembolic, including atherothrombotic and unclassified thrombotic strokes, were 
labeled “nonlacunar.” Hemorrhagic strokes identified by ARIC were censored at the time of their 
occurrence. 
 
Bio-Repository of DNA in Stroke (BRAINS) 
The Bio-Repository of DNA in Stroke (BRAINS) is an international study recruiting highly phenotyped 
patients with stroke. For the purposes of the current work all patients were Caucasians. Diagnosis of 
stroke was confirmed using positive imaging (MRI or CT) and ischemic stroke subtypes were assigned 
using TOAST criteria, based on clinical, imaging and risk factor data. Controls were European-Ancestry, 
stroke-free participants from the shared WTCCC controls, a prospectively collected cohort of 
individuals born in 1958 (1958 Birth Cohort). The cohort has been described in detail elsewhere.9 
 
Cardiovascular Health Study (CHS) 
The CHS is a population-based cohort study of risk factors for coronary heart disease (CHD) and stroke 
in adults ≥65 years conducted across four field centers in the United States.6 The original predominantly 
white cohort of 5,201 persons (4,964 whites) was recruited in 1989-1990 from a random sample of 
people on Medicare eligibility lists and an additional 687 African-Americans were enrolled subsequently 
(1992-93) for a total sample of 5,888. Race was determined by self-identification at interview. In 
addition to the 5 categories used in the ARIC study, participants were also asked a second question as to 
whether they considered themselves to be of Hispanic origin. To reduce the possibility of confounding 
by population structure, these analyses were limited to participants of self-described European-ancestry. 
The study sample for these analyses includes participants who were free of CVD at baseline, had blood 
samples drawn at their baseline examination, consented to genetic testing, had DNA available, and had 
successful genome-wide genotyping assay. Participants were examined annually from enrollment to 
1999, and since then continue to be under surveillance for stroke. Since baseline, participants have also 
been contacted twice a year to identify potential cardiovascular events, including stroke. In addition, all 
hospitalizations were screened for potential stroke events. For suspected events, information was 
collected from the participant or next of kin, from medical records, and, if needed, from the participant's 
physician. When available, CT and/or MRI scans or reports were reviewed centrally. Final adjudication 
of the occurrence of stroke, stroke types, and subtypes was undertaken by vascular neurologists at a 
consensus conference using all available information. Strokes were classified as ischemic if there was 
imaging (CT or MRI within 4 weeks), surgical or autopsy evidence excluding a hemorrhage, or in the 
absence of such direct evidence (in <10% of cases in FHS and Rotterdam, none in CHS) if the 
preponderance of indirect evidence (e.g. deficit limited to one limb or completely resolved within 72 
hours, atrial fibrillation in persons not on anticoagulants) suggested the event was an ischemic rather 
than a hemorrhagic stroke. A stroke was classified as hemorrhagic if there was imaging, surgical, lumbar 
puncture or autopsy evidence of hemorrhage, and in the absence of direct evidence to the contrary, when 
the participant lost consciousness permanently or died within hours after onset of focal signs. The stroke 
type was defined as unknown if there was insufficient information available to categorize the event as 
ischemic or hemorrhagic. All ischemic and hemorrhagic strokes and strokes of unknown type were 
included in the analyses of total stroke with one exception: subarachnoid hemorrhages (n=28 across all 
studies) were excluded from these analyses since the heritability, risk factors and pathophysiologic 
mechanisms underlying subarachnoid hemorrhages are distinctly different from other stroke subtypes. 
Persons with a subarachnoid hemorrhage were censored at the time of the event. Only known ischemic 
strokes were included in the analysis of ischemic stroke. In secondary analyses we related those SNPs 
which reached genome-wide significance in our initial GWAS to the specific ischemic stroke subtype of 
 
 
10 
 
atherothrombotic stroke, also called atherothrombotic brain infarction (ABI). We used the best available 
definitions of definite and possible ABI in each cohort; both large artery atherosclerotic strokes and 
small-vessel or lacunar strokes were included in this phenotype, events known to be cardioembolic were 
excluded. For the analysis of ABI, participants were censored when they developed an alternative type 
of stroke.  
 
deCODE Genetics 
Cases, irrespective of age, were identified from a registry of individuals diagnosed with ischemic stroke 
or TIA at Landspitali University Hospital in Reykjavik, the only tertiary referral centre in Iceland, 
during the years 1993 to 2006. The ischemic stroke or TIA diagnoses were based on standard WHO 
criteria and imaging evidence (either CT or MRI), and were clinically confirmed by neurologists. 
Eligible patients who survived the stroke were invited to participate the genetic study, either by 
attending a recruitment center for deCODE’s genetic studies, or they were visited at their home by a 
study nurse. Control subjects were participants from a large variety of genetic programs at deCODE. 
Individuals with confirmed stroke (identified by cross-matching with hospital lists), who had 
participated in genetic studies other than those of cardiovascular diseases (CVD) (but not participated in 
CVD studies) were excluded as controls. 
 
Heart Protection Study (HPS) 
The Heart Protection Study (HPS) was a large randomized trial involving individuals at increased risk of 
vascular events. Between 1994-1997 20,536 men and women aged 40-80 years were recruited from 69 
collaborating hospitals in the United Kingdom (with ethics committee approval). Participants were 
eligible for inclusion provided they had non-fasting blood total cholesterol concentrations of at least 135 
mg/dL (3.5 mmol/L) and either a previous diagnosis of coronary disease, ischemic stroke, other 
occlusive disease of non-coronary arteries, diabetes mellitus, or (if were men 65 years or older) treated 
hypertension. None of them was on statin therapy. At the initial screening visit, all participants provided 
written consent and began a “run-in” phase involving 4 weeks of placebo followed by 4 to 6 weeks of 40 
mg simvastatin daily, after which compliant and eligible individuals were randomly allocated 40 mg 
simvastatin daily or matching placebo for approximately 5 years. Individuals entering HPS with a 
clinical diagnosis of ischemic stroke were used as cases in the METASTROKE study. Individuals 
entering HPS with pre-existing diabetes but no history of cerebrovascular disease, coronary heart disease 
or peripheral vascular disease were used as controls. 
 
The Heart and Vascular Health Study (HVH) 
The setting for this study was Group Health (GH), a large integrated health care system in western 
Washington State. Data were utilized from an ongoing case-control study of incident myocardial 
infarction (MI) and stroke cases with a shared common control group. Methods for the study have been 
described previously10-12 and are briefly summarized below. The study was approved by the human 
subjects committee at GH, and written informed consent was provided by all study participants. All 
study participants were GH members and aged 30-79 years. MI and stroke cases were identified from 
hospital discharge diagnosis codes and were validated by medical record review. Controls were a 
random sample of GH members frequency matched to MI cases on age (within decade), sex, treated 
hypertension, and calendar year of identification. The index date for controls was a computer-generated 
random date within the calendar year for which they had been selected. For stroke cases, the index date 
was the date of admission for the first acute stroke. Participants were excluded if they were recent 
enrollees at GH, had a history of prior stroke, or if the incident event was a complication of a procedure 
 
 
11 
 
or surgery. Trained medical record abstractors collected eligibility and risk factor information from a 
review of the GH medical record using only data available prior to the index date and through a 
telephone interview. Medication use was ascertained using computerized GH pharmacy records. A 
venous blood sample was collected from all consenting subjects, and DNA was extracted from white 
blood cells using standard procedures. Diagnostic criteria for ischemic stroke were adopted from the 
Cardiovascular Health Study13 These 
criteria included (1) rapid onset of neurologic deficit or subarachnoid hemorrhage, (2) deficit persisting 
for longer than 24 hours unless computed tomography or magnetic resonance imaging show evidence of 
permanent damage, and (3) no underlying brain trauma, tumor, or infection to cause symptoms. 
These analyses were limited to ischemic stroke cases, namely those satisfying 1 or more of the following 
criteria: (a) Focal deficit, without evidence of blood on CT or MRI, (b) Focal deficit, with mottled 
appearance in the appropriate location on CT, or (c) surgery or autopsy evidence of infarction. Among 
ischemic strokes, the subtypes were defined as follows: Lacunar stroke (“SVD”) required either: (a) 
CT/MRI demonstrates a deep area of infarction (decreased density) less than 2 cm. across, or (b) A 
normal CT, but the clinical syndrome is typical of a lacunar infarction, that is: a pure motor stroke, a 
pure sensory stroke, hemiparesis plus ataxia, or dysarthria plus a clumsy hand. Embolic stroke (“CE”) 
required either (a) a recognized source of emboli such as atrial fibrillation, endocarditis, mitral stenosis, 
thrombus in heart, recent MI or cardiac surgery, or (b) a mottled appearance consistent with infarction 
on the CT. Atherosclerotic infarction (“LAA”) when there is no apparent source of emboli or evidence 
of lacunar infarction and there is evidence of large vessel atherosclerosis by carotid ultrasound or 
angiography. 
 
The Ischemic Stroke Genetics Study (ISGS)/ Siblings With Ischemic Stroke Study (SWISS) 
The Siblings with Ischemic Stroke Study (SWISS) is a multicenter affected sibling pair study enrolling 
probands with ischemic stroke at 66 US medical centers and 4 Canadian medical centers.14 All probands 
are adult men and women over the age of 18 years diagnosed with ischemic stroke confirmed by a study 
neurologist on the basis of history, physical examination and CT or MR imaging of the brain. 
Additionally all probands were required to have at least one living sibling with a history of stroke. 
Siblings were enrolled using proband-initiated contact or direct contact when permitted by Institutional 
Review Boards.15 Clinical exclusion criteria mirrored that in ISGS. Concordant siblings had their 
diagnosis of ischemic stroke confirmed by review of medical records by a central vascular neurology 
committee. Subtype diagnoses were assigned to the index strokes of probands and concordant siblings 
according to TOAST criteria.16 Readily available US controls were utilized, including stroke-free 
participants from the Baltimore Longitudinal Study of Aging and the National Institute of Neurological 
Diseases and Stroke neurologically normal control series taken from the Coriell Cell Repositories. All 
controls had been previously genotyped and described in detail elsewhere. 
The Ischemic Stroke Genetic Study (ISGS) is a multicenter study where inpatient cases were recruited 
from five United States academic medical centers.20 Cases are adult men and women over the age of 18 
years diagnosed with first-ever ischemic stroke confirmed by a study neurologist on the basis of history, 
physical examination and CT or MR imaging of the brain who were enrolled within 30 days of onset of 
stroke symptoms. Cases exclusion criteria include: a mechanical aortic or mitral valve at the time of the 
index ischemic stroke, central nervous system vasculitis, bacterial endocarditis, cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), Fabry disease, 
homocystinuria, mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS), 
or sickle cell anemia. Stroke severity at enrollment was assessed using the NIH Stroke Scale with the 
diagnostic evaluation including head CT (95%) or MRI (83%), electrocardiography (92%), cervical 
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arterial imaging (86%), and echocardiography (74%). Medical records from all cases were centrally 
reviewed by a vascular neurology committee and assigned ischemic stroke subtype diagnoses according 
to criteria from the Trial of ORG10172 (TOAST), the Oxfordshire Community Stroke Project, and the 
Baltimore-Washington Young Stroke Study. 
 
Rotterdam 
The Rotterdam Study is a population-based cohort study among inhabitants of a district of Rotterdam 
(Ommoord), The Netherlands, and aims to examine the determinants of disease and health in the elderly 
with a focus on neurogeriatric, cardiovascular, bone, and eye disease.21 In 1990-1993, 7,983 persons 
participated and were re-examined every 3 to 4 years. After enrollment in the Rotterdam Study, 
participants are continuously monitored for incident stroke through automated linkage of the study 
database with files from general practitioners. Nursing home physicians' files and files from general 
practitioners of participants who moved out of the district are scrutinized as well. Additional information 
is obtained from hospital records. Potential strokes are reviewed by research physicians and verified by 
an experienced stroke neurologist. Stroke is defined as rapidly developing clinical signs of focal or 
global disturbance of cerebral function with no apparent cause other than a vascular origin. History of 
stroke at baseline was assessed during the baseline interview and verified in medical records. Strokes are 
further classified as cerebral infarction or intracerebral hemorrhage based on neuroimaging reports. If 
neuroimaging is lacking, a stroke is classified as unspecified. Subarachnoid hemorrhages were excluded. 
Ischemic strokes are subtyped into large-vessel disease, small vessel disease, or cardio-embolic based on 
all available clinical and imaging data. If insufficient information is present to reliably subtype into one 
of three categories, the ischemic stroke is classified as unspecified ischemic stroke. For the current study, 
too few cases of ischemic stroke subtypes were present to reliably perform statistical analyses. 
Participants were followed from baseline to stroke, death, last health status update when they were 
known to be stroke-free, or January 1, 2005, whichever came first. Follow-up was complete up to 
January 1, 2005, for 99.1% of potential person-years. 
 
 
The Sahlgrenska Study of Ischemic Stroke (SAHLSIS) 
SAHLSIS has been described in more detail previously.17 In brief, Caucasian patients (n=1088) under 70 
years of age who presented with first-ever or recurrent acute ischemic stroke were recruited 
consecutively at four stroke units in western Sweden. Healthy Caucasian community controls (n=600) 
matched for age and sex from the same geographic area were randomly selected from participants in a 
population-based survey or the Swedish Population Register. All patients were examined by a physician 
trained in stroke medicine, at baseline and at a follow-up three months after inclusion. All patients 
underwent ECG and neuroimaging with computed tomography (CT) and/or magnetic resonance imaging 
(MRI). Extracranial carotid and vertebral duplex ultrasound, MR angiography, catheter angiogram, 
transcranial Doppler ultrasound, transthoracic and/or transesophageal echo-cardiography were 
performed when clinically indicated. IS was defined as an episode of focal neurological deficits with 
acute onset and lasting >24 hours or until death, with no apparent non-vascular cause, and no signs of 
primary hemorrhage on brain imaging. All participants provided written informed consent prior to 
enrolment. For participants who were unable to communicate, consent was obtained from their next-of-
kin. This study was approved by the Ethics Committee of the University of Gothenburg.  
Whole blood was isolated from all individuals for genotyping. Plasma was additionally isolated 
from the first 600 patients and controls for protein measurement.  Genotyping for 600 controls was 
performed using the Illumina Human OmniExpress 750K array at the Broad Institute at Harvard 
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Medical School (Cambridge USA). Genotype data for rs7906302 and rs1338423 were extracted from 
the above array for all genotyped controls in SAHLSIS. Genotyping was performed blinded to 
case/control status. 
 
Web Resources 
The URLs for data presented herein are as follows: 
The 1000 Genomes Project: http://www.1000genomes.org/ 
GWAMA software: http://www.well.ox.ac.uk/gwama/ 
METASOFT software: http://genetics.cs.ucla.edu/meta/ 
QUANTO software: http://biostats.usc.edu/software.html 
Ensemble Variant Effect Predictor tool: http://www.ensembl.org/info/docs/tools/vep/index.html 
SNP Annotation and Proxy Search (SNAP): http://www.broadinstitute.org/mpg/snap/ 
The Genotype-Tissue Expression project (GTEx) project: http://www.gtexportal.org/home/ 
The Wellcome Trust Sanger Institute Genevar (GENe Expression VARiation) tool: 
http://www.sanger.ac.uk/resources/software/genevar/ 
LocusZoom software: http://csg.sph.umich.edu/locuszoom/ 
 
Accession Numbers 
The dbGaP accession number for GEOS data reported in this paper is phs000292.v1.p1. 
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Supplemental Tables  
 
Supplemental Table I. Study design and characteristics of participating studies in the discovery phase.   
 
 CADISP GEOS EA GEOS AA MILANO RACE 1 RACE 2 SIFAP WTCCC-UK 
Cases 555 448 381 201 1218 339 981 382 
Stroke Subtype*         
Cardioembolic (CE) 211 90 74 37 226 67 170 44 
Large Artery Atherosclerosis (LA) 67 37 23 34 201 56 184 79 
Small Vessel (SV) 31 54 77 12 190 42 104 91 
Other known causes 18 29 24 N/A 15 6 164 NA 
Undetermined causes 228 238 183 67 586 168 331 158 
First-ever ischemic stroke (%) ~100 100 100 100 100 100 N/A 100 
CT/MRI Brain Imaging (%) 100 97.80 96.3 100 100 100 N/A 100 
Age, mean (SD) 43.73 (9.9) 41.0  (7.0) 275 (61.4) 45.0(10.4) 50.1 (9.9) 50.2 (9.2) 41.7 (7.4) 51.9 (7.3) 
Male, n (%) 339 (61.1) 41.9 (6.8) 207 (54.3) 120 (60.9) 638 (52.4) 272 (80.4) 599 (61.1) 228 (59.7) 
Controls 9259 498 352 407 1158 3295 1825 5175 
Age, mean (SD) N/A 39.5 (6.7) 40.0 (6.8) 50.8 (8.1) 51.9 (7.9) 60.9 (13.2) 55.2 (11.6) 52 (?) 
Male, n (%) N/A 282 (56.6) 196 (55.7) 357 (87.8) 613 (53.0) 1838 (55.8) 899 (49.3) 2611 (50.5) 
Control Source Internal Internal Internal Internal External External 
External 
(KORA 
study) 
External 
(1958 
British Birth 
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cohort and 
the UK 
Blood 
Service 
control group 
N/A: not available 
* defined by TOAST criteria 
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Supplemental Table II. Study design and characteristics of participating studies in the validation phase.   
 
 ASGC Munich WTCCC2-immunochip-
Belgium 
WTCCC2-
immunochip-
Germany 
WTCCC2-
immunochip-
Krakow 
WTCCC2-
immunochip-
Sweden 
WTCCC2-
immunochip-
UK 
Cases 227 275 97 96 93 96 119 
First-ever ischemic stroke (%) N/A 94.2% N/A N/A N/A N/A N/A 
CT/MRI Brain Imaging (%) 97.4 100 100 N/A 100 N/A 100 
Age (mean ± SD) 52.3 (8.7) 48.8 (8.51) 49.9 ± 10.19 48.7 ± 10.07 51.0 ± 8.54 53.4 ± 6.49 49.8 ± 9.9 
Male Participants, n (%) 151 (66.5) 188 (68.4) 67 (71.1) 65 (67.7) 58 (62.3) 69 (71.9) 73 (61.3) 
Controls 1244 797 319 2344 255 996 1790 
Age 66.3 (7.5) 62.7(10.9) N/A N/A N/A N/A N/A 
% Males 625 (50.2) 410 (51.4) 152 (47.6) 1186 (50.3) 94 (36.9) 269 (27.0) 741 (41.4) 
Control Source Internal External Internal Internal Internal Internal Internal 
N/A: not available 
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Supplemental Table III. Genotyping and analysis methods used by each participating studies in discovery phase 
 
 CADISP GEOS MILANO SIFAP1 RACE 11 RACE 2 WTCCC2-UK 
Genotyping Platform 
Human610-Quad 
BeadChip 
(Illumina, San 
Diego, USA) 
Illumina 
HumanOmni1-
Quad_v1-0_B 
Cases: Illumina 
Human610-Quad 
v1_B or 
Human660W-Quad 
v1_A ; Controls: 
Illumina 
HumanHap610-Quad  
Illumina Human 
Omni 2.5M-Quad 
array 
 
Illumina 
Human660W-
Quad 
Illumina 
HumanOmni 
express 
Cases: Illumina 
Human660W-
Quad ; Controls: 
Illumina 
Human1.2M-Duo 
QC filters  
Individuals with a 
call rate <0.95, sex 
mismatch and 
duplicates were 
excluded.  
Individuals with 
unexpected 
relatedness, 
gender mismatch, 
population outliers 
were excluded;  
SNPs with missing 
call rate >=5%, 
HWE P<0.0001, 
monomorphic 
SNP were 
excluded 
Exclude individuals 
with  
unexpected 
relatedness, gender 
mismatch, population 
outliers;  
Exclude SNPs 
genotyped in <99% 
of individuals, HWE 
p<0.0001 or 
MAF<0.01 
 
Exclude SNPs with 
missing call rate 
>=5%, HW 
P<0.0001, 
monomorphic SNP 
 
Exclude SNPs 
with missing 
call rate >=5%, 
HW P<0.0001, 
monomorphic 
SNP 
Exclude SNPs 
with missing call 
rate >=5%, HW 
P<0.0001, 
monomorphic 
SNP 
Exclude  
Samples as outliers 
on call rate, 
ancestry, 
heterozygosity and 
average probe 
intensity using a 
Bayesian 
clustering 
algorithm. Samples 
were also removed 
if they exhibited 
gender or cryptic 
relatedness with 
other WTCCC2 
samples; Exclude 
SNPs genotyped in 
<99% of 
individuals, HWE 
p<0.0001 or 
MAF<0.01 
Pre-phasing software SHAPE-IT IMPUTE2 no prephasing IMPUTE2 IMPUTE2 IMPUTE2 IMPUTE2 
Imputation software IMPUTE2 IMPUTE2 IMPUTE2 IMPUTE2 IMPUTE2 IMPUTE2 IMPUTE2 
1KG  reference panel 
used (website link) 
1000G Phase 1 
integrated variant 
set (Mar 2012) 
1000G phase 1 
interim set (June 
2011) 
1000G Phase 1 
integrated variant set 
(Mar 2012) 
1000G phase 1 
interim set (June 
2011) 
1000G phase 1 
interim set 
(June 2011) 
1000G phase 1 
interim set (June 
2011) 
1000G Phase 1 
integrated variant 
set (Mar 2012) 
Model adjustments sex, PC1-10 age, study phase, PC1 sex, PC1 & PC5 Age, sex, PC1-5 
adjusted for 
age, sex, PCs1-
adjusted for age, 
sex, PCs1-10 
sex 
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10 
1  For RACE and SIFAP studies where controls were genotyped separately from cases, raw scan data from cases and controls were clustered together 
to obtain a combined set of genotypes. In addition, a subset of control subjects (28 control subjects for SIFAP and 95 control subjects for RACE) 
were re-genotyped together with cases to provide cross-set duplicates. This joint clustering was used to minimize possible artifactual differences in 
allelic frequency between cases and controls due to the fact that they were genotyped at different times and the cross-set duplicates were used to 
detect such artifacts that may have occurred. 
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Supplemental Table IV. Genotyping and analysis methods used in the validation studies. 
 
 ASGC Munich WTCCC2-immunochip-
Belgium 
WTCCC2-
immunochip-
Germany 
WTCCC2-
immunochip-
Krakow 
WTCCC2-
immunochip-
Sweden 
WTCCC2-
immunochip-UK 
Genotyping Platform 
Human610-Quad 
BeadChip 
(Illumina, San 
Diego, USA) 
Human660W-
Quad (cases) / 
Human 550 
(controls) 
Illumina 
Immunochip 
Illumina 
Immunochip 
Illumina 
Immunochip 
Illumina 
Immunochip 
Illumina 
Immunochip 
QC filters  
Call rate <97%, 
MAF <0.5%, P-
HWE<1x10-4, 
ambiguous SNPs, 
SNPs not in 
1000G, SNPs that 
couldn't be lifted 
to B37 
Bayesian 
clustering 
approach 
 
Exclude individuals 
with high 
heterozygosity, high 
missingness, 
relatedness to other 
individuals or if they 
did not segregate 
with HapMap II 
CEU individuals 
based on PCA 
analysis using 
EIGENSTRAT. 
Exclude SNPs with 
high missingness, 
deviation from 
HWE, low MAF 
(<0.01) 
Exclude individuals 
with high 
heterozygosity, 
high missingness, 
relatedness to other 
individuals or if 
they did not 
segregate with 
HapMap II CEU 
individuals based 
on PCA analysis 
using 
EIGENSTRAT. 
Exclude SNPs with 
high missingness, 
deviation from 
HWE, low MAF 
(<0.01) 
Exclude individuals 
with high 
heterozygosity, 
high missingness, 
relatedness to other 
individuals or if 
they did not 
segregate with 
HapMap II CEU 
individuals based 
on PCA analysis 
using 
EIGENSTRAT. 
Exclude SNPs with 
high missingness, 
deviation from 
HWE, low MAF 
(<0.01) 
Exclude individuals 
with high 
heterozygosity, 
high missingness, 
relatedness to other 
individuals or if 
they did not 
segregate with 
HapMap II CEU 
individuals based 
on PCA analysis 
using 
EIGENSTRAT. 
Exclude SNPs with 
high missingness, 
deviation from 
HWE, low MAF 
(<0.01) 
Exclude individuals 
with high 
heterozygosity, 
high missingness, 
relatedness to other 
individuals or if 
they did not 
segregate with 
HapMap II CEU 
individuals based 
on PCA analysis 
using 
EIGENSTRAT. 
Exclude SNPs with 
high missingness, 
deviation from 
HWE, low MAF 
(<0.01) 
Pre-phasing software Minimac MACH IMPUTE2 IMPUTE2 IMPUTE2 IMPUTE2 IMPUTE2 
Imputation software Mach MACH IMPUTE2 IMPUTE2 IMPUTE2 IMPUTE2 IMPUTE2 
1KG  reference panel 
used (website link) Phase 1 (v3) 
1000G Phase 1 
integrated variant 
set 
1000G Phase 1 
integrated variant set 
(Mar 2012); 
1000G Phase 1 
integrated variant 
set (Mar 2012); 
1000G Phase 1 
integrated variant 
set (Mar 2012); 
1000G Phase 1 
integrated variant 
set (Mar 2012); 
1000G Phase 1 
integrated variant 
set (Mar 2012); 
Model adjustments 
age, sex and the 
first 4 principal 
components of 
ancestry 
No covariates gender, 5 PCs gender, 10 PCs gender, 5 PCs gender, 5 PCs gender, 10 PCs 
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Supplemental Table V. Study design and characteristics of METASTROKE cohorts. 
Cohorts Number of cases 
Number of 
controls 
Number (%) of 
cases < 60 years Mean Age (yrs) Study design 
ARIC 385 8803 42 (10.9) 57.3 ± 5.3 Population-based, prospective 
BRAINS 361 444 90 (24.9) 74.4 ± 14.2 Cross-sectional 
CHS 454 2817 0 (0) 81.6 ±6.11 Population-based, prospective 
deCODE 2391 26970 N/A 73.3 ±12.1 Cross-sectional 
HPS 578 468 231 (40.0) 64.9 ± 7.5 Cross-sectional 
HVH 566 1290 97 (17.1) 69.2 ± 8.6 Cross-sectional 
ISGS/SWISS 1070 2329 N/A 66.5 ±13.6 Cross-sectional 
Rotterdam 367 5396 N/A 70.8 ± 7.5 Population-based, prospective 
N/A: information not available 
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Supplemental Table VI.  SNPs with suggestive associations with early-onset ischemic stroke and their proxy SNPs in chr10 region. 
       LD with rs11196288 (r2/D’)  
SNP1 Position (hg18) variant 
Association p-
value for young-
onset stroke in 
the Discovery 
Phase 
AFR_MAF ASN_MAF EUR_MAF CEU YRI CHB/JPT Functional Prediction 
rs4075717 115037998 G/A 4.15E-05 0.02 0.21 0.04 0.618/0.844 NA 0.117/0.452  
rs12219131 115038675 C/T 1.65E-05 0.23 0.21 0.05 0.618/0.844 0.011/0.847 0.117/0.452  
rs11196283 115039246 C/T 1.46E-05 0.22 0.21 0.04 0.529/0.727 0.002/0.125 0.103/0.412  
rs4917648 115042323 A/G 3.50E-06 0.23 0.2 0.06 0.618/0.844 0.011/1.000 0.196/0.600  
rs11196284 115045236 C/T 1.29E-05 0.01 0.19 0.04 0.737/1 NA 0.173/0.616  
rs11196287 115052431 A/C 6.25E-07 0.04 0.38 0.04 1/1 0.330/0.574 0.765/1.000  
rs12218673 115053330 C/T 1.36E-05 0.02 0.34 0.04 0.737/1 0.001/1.000 0.960/1.000  
rs61872854 115055671 A/G 2.85E-07 0.05 0.35 0.04 1/1 NA 1/1  
rs7906302 115056097 G/T 1.09E-06 0.15 0.41 0.05 0.881/1 0.231/1.000 0.765/1.000  
rs4918806 115057210 C/G 4.44E-07 0.22 0.41 0.05 1/1 0.193/1.000 0.765/1.000 Regulatory 
rs11196288 115057443 A/G 1.24E-07 0.07 0.35 0.04 -- -- --  
rs11196289 115059235 C/T 5.04E-07 0.04 0.35 0.04 0.881/1 0.590/1.000 0.961/1.000  
rs1338423 115060426 G/A 6.52E-07 0.07 0.36 0.04 0.881/1 0.793/1.000 0.961/1.000 Regulatory 
rs10885429 115061139 A/T 2.74E-06 0.14 0.42 0.06 0.881/1 0.231/1.000 0.737/1.000  
rs4918807 115062997 A/G 1.22E-06 0.07 0.36 0.04 0.881/1 1/1 0.961/1.000  
rs4918809 115063701 C/T 3.82E-06 0.18 0.41 0.06 0.786/1 0.217/1.000 0.737/1.000  
rs4918810 115064197 C/T 5.17E-07 0.07 0.35 0.04 0.881/1 1/1 1/1  
1 Twelve SNPs with suggestive associations (P<5.0x10-6 in the Discovery Phase, trans-ethnic meta-analysis) are in bold; proxy SNPs (unbold) were 
identified as having r2>0.8 with any of the 12 stroke-associated SNPs in ≥ 2 reference populations (CEU, CHB/JPT or YRI) based on 1000 Genomes 
Pilot data. 
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Supplemental Table VII.   Top association signals for early-onset ischemic stroke 
Chr SNP Position Candidate 
Gene(s) 
Effect 
allele 
Other 
allele  
EAF Discovery Stage Follow-up Stage Discovery + Follow-upa 
       OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P 
1. European-only GWA meta-analysis 
1q24.2 
rs1800594 
rs9332599 
169510524 
169512980 
F5 
A 
G 
G 
A 
0.69 
0.67 
1.23 (1.13-1.34) 
1.20 (1.11-1.30) 
1.39E-06 
3.90E-06 
1.08 (0.94 – 1.24) 
1.05 (0.93 – 1.19) 
0.30 
0.39 
1.18 (1.11-1.27) 
1.16 (1.08-1.23) 
2.26E-06 
1.16E-05 
2p15 
rs74739745 
rs140510319 
61313269 
61367943 
KIAA1841-
LOC39803 
G 
C 
A 
A 
0.98 
0.97 
1.88 (1.49-2.37) 
1.75 (1.40-2.19) 
8.52E-08 
8.42E-07 
0.77 (0.51 – 1.17) 
0.82 (0.54 - 1.25) 
0.22 
0.35 
1.53 (1.25-1.87) 
1.49 (1.23-1.81) 
2.78E-05 
6.13E-05 
14q23.3 
rs12434854 
rs12435908 
65896234 
66121468 
FUT8 
G 
A 
A 
C 
0.93 
0.93 
1.38 (1.21-1.58) 
1.37 (1.20-1.56) 
2.07E-06 
3.25E-06 
1.08 (0.87 – 1.34) 
1.10 (0.89 – 1.36) 
0.50 
0.39 
1.29 (1.15-1.45) 
1.29 (1.15-1.44) 
7.98E-06 
7.19E-06 
17q25.3 
rs6565653 
rs12601526 
78201783 
78202358 
SLC26A11 
T 
C 
G 
T 
0.46 
0.50 
1.21 (1.12-1.31) 
1.21 (1.12 -1.31) 
1.08E-06 
1.08E-06 
1.12 (0.87 – 1.44) 
1.05 (0.81 – 1.36) 
0.39 
0.71 
1.20 (1.12-1.29) 
1.20 (1.11-1.29) 
5.51E-07 
1.14E-06 
2. Trans-ethnic GWA meta-analysis 
 
10q25.3 
rs61872854 
rs11196288 
115055671 
115057443 
Intergenic 
(TCF7L2 – 
HABP2) 
A 
G 
G 
A 
0.05 
0.05 
1.39 (1.22-1.57) 
1.39 (1.23-1.58) 
2.85E-07 
1.24E-07 
1.80 (1.06-3.05) 
1.80 (1.06-3.05) 
0.03 
0.03 
1.40 (1.25-1.59) 
1.41 (1.25-1.59) 
2.21E-08 
9.50E-09 
             
a Study-specific estimates were meta-analyzed using fixed effect model 
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Supplemental Table VIII. Top associated SNPs in GWAS analysis of stroke subtypes 
Chr Position SNP Candidate 
Gene(s) 
Subtype Effect 
allele 
Other 
allele  
EAF Association with stroke 
subtype 
 
        OR (95% CI) P-value Heterogeneity I2 
1. European-only  
12 21323611 rs2417957 SLCO1B1 LA C T 0.97 0.36 (0.25-0.51) 2.64E-08 34% 
10 18729855 rs72786098 CACNB2 SV G A 0.97 0.28 (0.18 – 0.44) 2.20E-08 60% 
2. Trans-ethnic association  
1 51298205 rs138364069 FAF1 LA C T 0.98 0.28 (0.18 – 0.42) 6.81E-09 36% 
1 51439456 rs3176471 CDKN2C LA A T 0.98 0.27 (0.17 – 0.43) 4.09E-08 57% 
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Supplemental Table IX. SNPs previously associated with ischemic stroke (and/or ischemic stroke subtypes) and their associations with early-
onset stroke  
       Association with early-onset ischemic strokea 
        European ancestryb   Trans-ethnicc 
Gene 
(ref) 
Chr Pos SNP (ref) RA RAF Previously 
reported 
OR (trait) 
Trait OR (95% CI) P   OR (95% CI) P 
NINJ212, 20 12 775199 rs11833579  A 0.23 1.06 (IS) IS 1.00 (0.91 – 1.09) 0.96   1.0 (0.94 – 1.07) 0.89 
       CE 1.00 (0.86 – 1.17) 0.99   1.10 (0.98 – 1.24) 0.12 
       LAA 1.05 (0.88 – 1.26) 0.56   1.05 (0.92 – 1.20) 0.46 
       SV 1.06 (0.87 – 1.31) 0.55   0.96 (0.83 – 1.11) 0.60 
       UE 0.93 (0.82 – 1.05) 0.23   0.99 (0.91 – 1.09) 0.91 
ALDH221 12 112233018 rs10744777 T 0.68 1.10 (IS) IS 1.08 (1.00 – 1.17) 0.05   1.05 (0.97 – 1.12) 0.21d 
       CE 1.03 (0.89 – 1.19) 0.68   1.03 (0.92 – 1.15) 0.64 
       LAA 1.06 (0.90 – 1.25) 0.46   1.10 (0.97 – 1.26) 0.13 
       SV 1.06 (0.86 – 1.29) 0.57   1.03 (0.82 – 1.30) 0.79d 
       UE 1.12 (1.00 – 1.25) 0.05   1.06 (0.92 – 1.21) 0.44d 
PITX212, 22 4 111710169 rs2200733  T 0.12 1.36 (CE) IS 1.15 (1.03 – 1.28) 0.01   1.11 (1.02 – 1.20) 0.02 
       CE 1.25 (1.03 – 1.52) 0.02   1.20 (1.03 -1.39) 0.02 
       LAA 1.20 (0.95 – 1.53) 0.13   1.15 (0.84 – 1.58) 0.37d 
       SV 1.29 (0.99 – 1.59) 0.06   1.12 (0.88 – 1.43) 0.34d 
       UE 1.15 (0.98 – 1.34) 0.06   1.14 (1.02 – 1.28) 0.03 
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ZFHX312, 23 16 73029160 rs7193343  T 0.23 1.25 (CE) IS 0.99 (0.90 – 1.09) 0.83   1.01 (0.94 – 1.08) 0.84 
       CE 1.04 (0.87 – 1.24) 0.68   1.02 (0.90 – 1.17) 0.68 
       LAA 1.06 (0.86 – 1.31) 0.57   1.10 (0.95 – 1.28) 0.19 
       SV 0.91 (0.71 – 1.15) 0.42   0.97 (0.83 – 1.13) 0.67 
       UE 1.06 (0.92 – 1.21) 0.42   1.04 (0.95 – 1.14) 0.42 
CDKN2B-AS112, 24 9 22115959 rs2383207  G 0.57 1.15 (LA) IS 1.10 (1.02-1.19) 0.01   1.08 (0.98 – 1.19) 0.13d 
       CE 1.08 (0.94 – 1.23) 0.29   1.06 (0.91 - 1.22) 0.45d 
       LAA 1.20 (1.03 - 1.40) 0.02   1.15 (0.96 – 1.38) 0.12d 
       SV 1.18 (0.98 – 1.41) 0.08   1.11 (0.94 – 1.32) 0.20d 
       UE 1.05 (0.95 – 1.17) 0.34   1.06 (0.94 – 1.20) 0.33d 
HDAC912, 25 7 19031935 rs11984041  A 0.09 1.39 (LA) IS 1.05 (0.93 – 1.19) 0.40   1.08 (0.99 – 1.11) 0.10 
       CE 0.96 (0.76 – 1.21) 0.71   1.04 (0.77 – 1.40) 0.80d 
       LAA 1.23 (0.95 – 1.59) 0.12   1.19 (0.91 – 1.54) 0.19 
       SV 1.14 (0.85 – 1.52) 0.38   1.05 (0.86 – 1.28) 0.62 
       UE 1.00 (0.84 – 1.19) 0.99   1.05 (0.92 – 1.19) 0.47 
6p215 6 44594159 rs556621  A 0.33 1.21 (LA) IS 0.95 (0.88 – 1.03) 0.20   0.97 (0.91 – 1.05) 0.54d 
       CE 1.00 (0.87 – 1.15) 0.98   1.02 (0.86 – 1.20) 0.82d 
       LAA 0.92 (0.78 – 1.09) 0.32   0.95 (0.83 – 1.08) 0.41 
       SV 1.00 (0.83 – 1.21) 0.97   1.02 (0.89 – 1.17) 0.80 
       UE 0.92 (0.83 – 1.03) 0.15   0.95 (0.85 – 1.07) 0.42d 
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Abbreviations: Chr=chromosome, pos=position, RA=risk allele, RAF=risk allele frequency, IS=ischemic stroke, CE=cardioembolic stroke, 
LAA=large artery atherosclerotic stroke, SV=small vessel stroke, UE=undetermined etiology stroke  
a All association results were obtained by meta-analyzing study-specific estimates. In trans-ethnic meta-analysis, odds ratios and p-values taken from 
the random effects model if evidence for between-study heterogeneity (i.e., I2 > 20%); otherwise, odds ratios and p-values based on fixed effect 
model. 
b A total of 2,567 total ischemic stroke cases, including 546 CE, 403 LAA, 294 SV and 1035 UE subtype cases. 
c A total of 4,501 total ischemic stroke cases, including 882 CE, 657 LAA, 591 SV and 1854 UE subtype cases. 
d SNPs with evidence for between-study heterogeneity 
 
 
ABO26 9 136149229 rs505922  C 0.32 1.07 (IS)  IS 1.15 (1.07- 1.25) 2.4x10-4   1.10 (1.04 – 1.17) 6.9x10-4 
      1.13 (CE)  CE 1.22 (1.06-1.40) 0.005   1.18 (1.06 – 1.31) 0.002 
      1.23 (LAA) LAA 1.21 (1.04 – 1.43) 0.02   1.18 (1.04 – 1.33) 0.008 
       SV 0.97 (0.80 – 1.17) 0.74   0.94 (0.82 – 1.07) 0.36 
       UE 1.18 (1.06 – 1.32) 0.002   1.10 (1.02 – 1.20) 0.02 
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Supplemental Figures 
 
Supplemental Figure I. QQ plot of (A) European-only meta-analysis and (B) trans-ethnic meta-analysis. 
 
 
 
 
 
 
(A) (B)
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Supplemental Figure II. European-ancestry GWAS results of stroke subtypes (A) cardioembolic, (B) large artery atherosclerotic, (C) small vessel 
stroke and (D) undetermined. 
(A) 
 
 
 (B) 
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Supplemental Figure II. (continue) 
(C) 
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(D)
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Supplemental Figure III Trans-ethnic GWAS results of stroke subtypes (A) cardioembolic, (B) large artery atherosclerotic, (C) small vessel stroke 
and (D) undetermined. 
(A) 
(B)
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Supplemental Figure III. (continued) 
(C) 
(D) 
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